USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Valion Bio completes formulation work for Entolirimod oral mucosal formulation

ACCESSWIRE +2 ·

VBIO
VBIO Valion Bio Inc
$2.14 -3.17%
View chart & analysis →
  1. 1Valion Bio has successfully completed formulation work to develop a new oral mucosal formulation of Entolirimod.
  2. 2Valion Bio holds an exclusive worldwide license from Statera Biopharma to develop and commercialize Entolirimod for the treatment of acute radiation syndrome.
  3. 3Interim CEO Dean Zikria said the changing nuclear energy landscape poses important questions for emergency preparedness systems.

So what's the key point?

Valion Bio has successfully created a way to apply the drug Entolirimod directly to the oral mucosa. The company holds the exclusive rights to develop and sell this medicine worldwide.

Source ACCESSWIRE +2 · View original ↗

Related 3-line summaries

Valion Bio announces government-funded study of Entolimod for intestinal injury ACCESSWIRE +1 · Aug 12PayPal Strengthens Dividend Payments and Shareholder Return Policies The Motley Fool +1 · 52m agoJamie Dimon's Cyber Risk Warning and SentinelOne's AI Revenue Growth The Motley Fool +1 · 52m ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news